ASX - By Stock
|
DXB |
Re:
Ann: Investor Presentation
|
|
BI
|
110 |
35K |
7 |
18/12/20 |
18/12/20 |
ASX - By Stock
|
110
|
35K
|
7
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Second Study to Include DMX-200 in COVID-19 Patients
|
|
BI
|
54 |
15K |
0 |
14/12/20 |
14/12/20 |
ASX - By Stock
|
54
|
15K
|
0
|
|
ASX - By Stock
|
DXB |
Re:
sub analysis overdue
|
|
BI
|
193 |
59K |
2 |
16/10/20 |
16/10/20 |
ASX - By Stock
|
193
|
59K
|
2
|
|
ASX - By Stock
|
DXB |
Re:
Load up
|
|
BI
|
170 |
64K |
3 |
30/09/20 |
30/09/20 |
ASX - By Stock
|
170
|
64K
|
3
|
|
ASX - By Stock
|
DXB |
Re:
Load up
|
|
BI
|
170 |
64K |
2 |
29/09/20 |
29/09/20 |
ASX - By Stock
|
170
|
64K
|
2
|
|
ASX - By Stock
|
DXB |
Load up
|
|
BI
|
170 |
64K |
1 |
29/09/20 |
29/09/20 |
ASX - By Stock
|
170
|
64K
|
1
|
|
ASX - By Stock
|
ZLD |
Re:
Ann: Thorney Becomes a Substantial Strategic Investor in Zelira
|
|
BI
|
101 |
23K |
1 |
23/09/20 |
23/09/20 |
ASX - By Stock
|
101
|
23K
|
1
|
|
ASX - By Stock
|
ZLD |
Re:
Ann: Thorney Becomes a Substantial Strategic Investor in Zelira
|
|
BI
|
101 |
23K |
2 |
23/09/20 |
23/09/20 |
ASX - By Stock
|
101
|
23K
|
2
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Positive Top-Line Results in DKD Phase 2 Clinical Study
|
|
BI
|
627 |
261K |
7 |
22/09/20 |
22/09/20 |
ASX - By Stock
|
627
|
261K
|
7
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Positive Top-Line Results in DKD Phase 2 Clinical Study
|
|
BI
|
627 |
261K |
1 |
17/09/20 |
17/09/20 |
ASX - By Stock
|
627
|
261K
|
1
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Positive Top-Line Results in DKD Phase 2 Clinical Study
|
|
BI
|
627 |
261K |
7 |
17/09/20 |
17/09/20 |
ASX - By Stock
|
627
|
261K
|
7
|
|
ASX - By Stock
|
ZLD |
Re:
Ann: Zenivol launches in Australia after TGA approves release
|
|
BI
|
52 |
17K |
6 |
16/09/20 |
16/09/20 |
ASX - By Stock
|
52
|
17K
|
6
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Positive Top-Line Results in DKD Phase 2 Clinical Study
|
|
BI
|
627 |
261K |
6 |
16/09/20 |
16/09/20 |
ASX - By Stock
|
627
|
261K
|
6
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Positive Top-Line Results in DKD Phase 2 Clinical Study
|
|
BI
|
627 |
261K |
9 |
15/09/20 |
15/09/20 |
ASX - By Stock
|
627
|
261K
|
9
|
|
ASX - By Stock
|
ZLD |
Re:
Cannabiods for athlete's in the media for pain
|
|
BI
|
35 |
9.1K |
8 |
14/09/20 |
14/09/20 |
ASX - By Stock
|
35
|
9.1K
|
8
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Positive Top-Line Results in DKD Phase 2 Clinical Study
|
|
BI
|
627 |
261K |
8 |
14/09/20 |
14/09/20 |
ASX - By Stock
|
627
|
261K
|
8
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Trading Halt
|
|
BI
|
356 |
127K |
8 |
14/09/20 |
14/09/20 |
ASX - By Stock
|
356
|
127K
|
8
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Positive Top-Line Results in DKD Phase 2 Clinical Study
|
|
BI
|
627 |
261K |
13 |
14/09/20 |
14/09/20 |
ASX - By Stock
|
627
|
261K
|
13
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Investor Presentation
|
|
BI
|
41 |
20K |
2 |
14/09/20 |
14/09/20 |
ASX - By Stock
|
41
|
20K
|
2
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Positive Top-Line Results in DKD Phase 2 Clinical Study
|
|
BI
|
627 |
261K |
5 |
14/09/20 |
14/09/20 |
ASX - By Stock
|
627
|
261K
|
5
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Trading Halt
|
|
BI
|
356 |
127K |
14 |
12/09/20 |
12/09/20 |
ASX - By Stock
|
356
|
127K
|
14
|
|
ASX - By Stock
|
ZLD |
Re:
Ann: Zelira Presentation ASX Small and Mid-Cap Conference
|
|
BI
|
46 |
12K |
7 |
11/09/20 |
11/09/20 |
ASX - By Stock
|
46
|
12K
|
7
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Trading Halt
|
|
BI
|
356 |
127K |
14 |
10/09/20 |
10/09/20 |
ASX - By Stock
|
356
|
127K
|
14
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Trading Halt
|
|
BI
|
356 |
127K |
4 |
10/09/20 |
10/09/20 |
ASX - By Stock
|
356
|
127K
|
4
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Trading Halt
|
|
BI
|
356 |
127K |
7 |
10/09/20 |
10/09/20 |
ASX - By Stock
|
356
|
127K
|
7
|
|
ASX - By Stock
|
DXB |
Re:
General Discussion
|
|
BI
|
134 |
39K |
3 |
08/09/20 |
08/09/20 |
ASX - By Stock
|
134
|
39K
|
3
|
|
ASX - By Stock
|
DXB |
Re:
Chartwatch - DXB
|
|
BI
|
350 |
135K |
1 |
31/08/20 |
31/08/20 |
ASX - By Stock
|
350
|
135K
|
1
|
|
ASX - By Stock
|
ZLD |
Re:
Ann: Appendix 4E & Financial Statements
|
|
BI
|
24 |
6.8K |
4 |
28/08/20 |
28/08/20 |
ASX - By Stock
|
24
|
6.8K
|
4
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Annual Report to shareholders
|
|
BI
|
34 |
14K |
4 |
27/08/20 |
27/08/20 |
ASX - By Stock
|
34
|
14K
|
4
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Annual Report to shareholders
|
|
BI
|
34 |
14K |
0 |
27/08/20 |
27/08/20 |
ASX - By Stock
|
34
|
14K
|
0
|
|
ASX - By Stock
|
ZLD |
Re:
Product to Market
|
|
BI
|
191 |
49K |
4 |
26/08/20 |
26/08/20 |
ASX - By Stock
|
191
|
49K
|
4
|
|
ASX - By Stock
|
DXB Biotech |
Re:
Valuation post positive results
|
|
BI
|
195 |
96K |
0 |
26/08/20 |
26/08/20 |
ASX - By Stock
|
195
|
96K
|
0
|
|
ASX - By Stock
|
DXB Biotech |
Re:
Valuation post positive results
|
|
BI
|
195 |
96K |
6 |
25/08/20 |
25/08/20 |
ASX - By Stock
|
195
|
96K
|
6
|
|
ASX - By Stock
|
DXB Biotech |
Re:
Valuation post positive results
|
|
BI
|
195 |
96K |
4 |
25/08/20 |
25/08/20 |
ASX - By Stock
|
195
|
96K
|
4
|
|
ASX - By Stock
|
ZLD |
Re:
#LetsTakeDown6cSellWall
|
|
BI
|
450 |
102K |
9 |
18/08/20 |
18/08/20 |
ASX - By Stock
|
450
|
102K
|
9
|
|
ASX - By Stock
|
DXB |
Re:
Chartwatch - DXB
|
|
BI
|
350 |
135K |
0 |
17/08/20 |
17/08/20 |
ASX - By Stock
|
350
|
135K
|
0
|
|
ASX - By Stock
|
ZLD |
Re:
#LetsTakeDown6cSellWall
|
|
BI
|
450 |
102K |
0 |
13/08/20 |
13/08/20 |
ASX - By Stock
|
450
|
102K
|
0
|
|
ASX - By Stock
|
ZLD |
Re:
#LetsTakeDown6cSellWall
|
|
BI
|
450 |
102K |
3 |
12/08/20 |
12/08/20 |
ASX - By Stock
|
450
|
102K
|
3
|
|
ASX - By Stock
|
ZLD |
Re:
#LetsTakeDown6cSellWall
|
|
BI
|
450 |
102K |
3 |
11/08/20 |
11/08/20 |
ASX - By Stock
|
450
|
102K
|
3
|
|
ASX - By Stock
|
DXB |
Re:
Chartwatch - DXB
|
|
BI
|
350 |
135K |
0 |
10/08/20 |
10/08/20 |
ASX - By Stock
|
350
|
135K
|
0
|
|
ASX - By Stock
|
ZLD |
Re:
Interview - Dr Richard Hopkins. Confirms upcoming launches.
|
|
BI
|
61 |
19K |
1 |
10/08/20 |
10/08/20 |
ASX - By Stock
|
61
|
19K
|
1
|
|
ASX - By Stock
|
DXB |
Re:
Chartwatch - DXB
|
|
BI
|
350 |
135K |
0 |
10/08/20 |
10/08/20 |
ASX - By Stock
|
350
|
135K
|
0
|
|
ASX - By Stock
|
ZLD |
Re:
Interview - Dr Richard Hopkins. Confirms upcoming launches.
|
|
BI
|
61 |
19K |
3 |
08/08/20 |
08/08/20 |
ASX - By Stock
|
61
|
19K
|
3
|
|
ASX - By Stock
|
ZLD |
Re:
Ann: ZLD Successfully Completes $8.75M Oversubscribed Placement
|
|
BI
|
31 |
12K |
3 |
03/08/20 |
03/08/20 |
ASX - By Stock
|
31
|
12K
|
3
|
|
ASX - By Stock
|
ZLD |
Re:
Ann: ZLD Successfully Completes $8.75M Oversubscribed Placement
|
|
BI
|
31 |
12K |
5 |
03/08/20 |
03/08/20 |
ASX - By Stock
|
31
|
12K
|
5
|
|
ASX - By Stock
|
ZLD |
#LetsTakeDown4cSellWall
|
|
BI
|
2 |
933 |
2 |
02/08/20 |
02/08/20 |
ASX - By Stock
|
2
|
933
|
2
|
|
ASX - By Stock
|
ZLD |
Re:
Ann: Trading Halt
|
|
BI
|
86 |
19K |
1 |
30/07/20 |
30/07/20 |
ASX - By Stock
|
86
|
19K
|
1
|
|
ASX - By Stock
|
ZLD |
Re:
Ann: Trading Halt
|
|
BI
|
86 |
19K |
1 |
30/07/20 |
30/07/20 |
ASX - By Stock
|
86
|
19K
|
1
|
|
ASX - By Stock
|
DXB |
Re:
Ann: Positive Top-Line Results in FSGS Phase 2a Clinical Study
|
|
BI
|
286 |
88K |
0 |
30/07/20 |
30/07/20 |
ASX - By Stock
|
286
|
88K
|
0
|
|
ASX - By Stock
|
ZLD |
Re:
#LetsTakeDown6cSellWall
|
|
BI
|
450 |
102K |
3 |
30/07/20 |
30/07/20 |
ASX - By Stock
|
450
|
102K
|
3
|
|